CSRWire - Keysight CTO Looks Back on 35 Years: One Score and

When CEO Ron Nersesian set up Keysight, he was clear about his desire to build an employee culture with strong business acumen, so all employees could work together to impact and benefit from the company's business results.

CSRWire - Keysight CTO Looks Back on 35 Years: One Score and Fifteen Years Ago

A Primer on Chronic Total Occlusion (CTO) Percutaneous Coronary Intervention for the Cath Lab

Scottie Jack on LinkedIn: #rsa #rsac #keysight #networkvisibility #networksecurity #networktesting

Why I Value our Corporate Social Responsibility (CSR) Commitments and Capabilities

Antegrade Chronic Total Occlusion Strategies: A Technical Focus for 2020

Prediction of successful guidewire crossing of below-the-knee chronic total occlusions using a Japanese scoring system - ScienceDirect

Why I Value our Corporate Social Responsibility (CSR) Commitments and Capabilities

Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)

STINGRAY LP Catheter - Clinical Data - Boston Scientific

What is CNAPP and How It Relates to Zero Trust (Featuring Chase Cunningham and Rick Moy)

CSRWire - Keysight CTO Looks Back on 35 Years: One Score and Fifteen Years Ago

Choice of CTO scores to predict procedural success in clinical practice. A comparison of 4 different CTO PCI scores in a comprehensive national registry including expert and learning CTO operators

Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)